Streetbeat News

Earnings

LIDR

MRDB

NCNO

In Wednesday's pre-market session, several information technology stocks showed significant movement. MariaDB (MRDB) led the gainers with a 75.4% increase, while AEye (LIDR) experienced the largest drop among the losers, declining by 17.8%. Notably, Ncino (NCNO) saw a 17.26% rise following its Q4 earnings report, and AEye's (LIDR) Q4 earnings also influenced its stock performance.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:05 pm

CPRX

Catalyst Pharmaceuticals (NASDAQ:CPRX) has received diverse analyst ratings over the past quarter, with a shift towards more bullish sentiments in recent months. The average 12-month price target for CPRX has risen to $29.29, indicating a positive outlook from financial experts. Analysts from firms like Oppenheimer, Cantor Fitzgerald, Citigroup, B of A Securities, and HC Wainwright & Co. have maintained or announced buy ratings, with price targets ranging from $23.00 to $34.00. Catalyst Pharmaceuticals, a biopharmaceutical company, has shown impressive financial performance with significant revenue growth, high net margin, and strong ROE and ROA, positioning it favorably in the market.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

SNX

TD Synnex (NYSE:SNX) has received consistent 'Indifferent' ratings from 4 analysts over the past three months, with a positive shift in the 12-month price target to $113.5, up 5.58% from $107.50. Analysts from Barclays, CFRA, RBC Capital, and JP Morgan have raised their price targets, reflecting a cautiously optimistic outlook despite TD Synnex's recent financial challenges, including a -11.33% revenue decline and below-industry-standard profitability metrics.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 1:00 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) reported its Q4 and fiscal year 2023 financial results, showing a decrease in cash, R&D, G&A, and total operating expenses compared to 2022. The company also reported a smaller net loss for both the quarter and the year. Enveric completed a warrant inducement transaction, raising $4.5 million. The company is advancing two drug candidates, EB-003 and EB-002, targeting mental health conditions, with plans to file regulatory applications in Australia and the U.S. Enveric discovered over 1,000 psychedelic-inspired compounds and strengthened its IP portfolio with ten new U.S. patents. It also signed term sheets for potential revenue of $261 million from out-licensing compounds.

Portfolio Pulse from Lara Goldstein

March 27, 2024 | 12:59 pm

LUXH

LuxUrban Hotels announced its expectation to expand its portfolio in FY24, focusing on acquiring higher-quality 3.5 to 4.5-star properties under long-term master lease agreements. This strategic move is aimed at generating increased Total Revenue per Available Room (TRevPAR).

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:53 pm

MRNA

Moderna Inc's stock rose after announcing positive Phase 3 trial results for its next-generation COVID-19 vaccine, MRNA-1283, and a $750 million investment from Blackstone Life Sciences for its flu program. The company's advancements in its mRNA vaccine pipeline were highlighted during its fifth Vaccines Day event, including the progression of multiple vaccine programs to late-stage clinical trials. MRNA-1283 showed a higher immune response than its licensed COVID-19 vaccine, and the investment will support the development of a combination flu and COVID-19 vaccine.

Portfolio Pulse from Adam Eckert

March 27, 2024 | 12:51 pm

LUXH

LuxUrban reported its preliminary Q4 2023 revenue to be $28.2 million, which is below the estimated $34.199 million.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:51 pm

PHX

PSIX

RVP

VRME

Insiders are buying shares in four companies under $4: Power Solutions International, VerifyMe, PHX Minerals, and Retractable Technologies. These purchases may indicate insider confidence in the companies' prospects. Power Solutions International recently announced its financial results, VerifyMe reported a profit, PHX Minerals posted upbeat sales, and Retractable Technologies reported a loss from operations.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 12:50 pm

CTAS

Cintas shares are trading higher following the announcement of better-than-expected Q3 financial results and an upward revision of its FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:49 pm

CTAS

Cintas Corporation has updated its fiscal year 2024 earnings and revenue forecasts, raising its EPS estimate from $14.35-$14.65 to $14.80-$15.00 and its revenue projection from $9.48B-$9.56B to $9.57B-$9.60B, compared to a consensus estimate of $9.558B.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:41 pm